Member access

4-Traders Homepage  >  News

News

Latest NewsCompaniesMarketsEconomy & ForexCommoditiesHot NewsMost Read NewsRecomm.Business LeadersVideosCalendar 

Tesaro Inc. : TESARO Details Niraparib Phase 1 Clinical Data Presented at the 2013 ASCO Annual Meeting

06/04/2013 | 11:12am US/Eastern
  • A RECIST Response Rate of 75% Was Achieved at the 300mg Dose in Patients With Platinum-Sensitive High Grade Serous Ovarian Cancer
  • A RECIST Response Rate of 50% Was Achieved Across All Dose Levels in Patients With Platinum Sensitive Ovarian Cancer and Germline BRCA Mutations
  • Progression Free Survival Exceeded One Year Among Platinum-Sensitive Ovarian Cancer Responders, Independent of BRCA Mutation Status

CHICAGO, June 4, 2013 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO), an oncology-focused biopharmaceutical company, today announced that final results from a Phase 1 trial of niraparib, an inhibitor of poly ADP-ribose polymerase (PARP), were presented this morning at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago.

At a dose of 300 milligrams once daily, which represents the dose and schedule that will be utilized in the Phase 3 studies, 75% (three of four patients) with platinum sensitive high grade serous ovarian cancer (HGSOC) achieved a RECIST response. Across all dose levels (30 milligrams to 400 milligrams daily), a RECIST response rate of 46% (6/13 patients) was observed in this population. A RECIST response rate of 50% (5/10 patients) was achieved in patients with platinum sensitive ovarian cancer and germline BRCA mutations. The median duration of response was 431 days for platinum sensitive germline BRCA patients and 444 days for platinum sensitive patients who were not germline BRCA mutation carriers.

In addition, 50% (two of the four patients) with BRCA-positive breast cancer achieved a response. Of the 10 patients with prostate cancer who had evaluable circulating tumor cell count (CTC) levels, seven (70%) had a reduction of > 30% in CTC count.

The ovarian cancer patients enrolled in this study had received a median of six previous regimens of systemic therapy. The breast cancer patients enrolled in this study had received a median of five previous regimens of systemic therapy.

Pharmacokinetic parameters were dose proportional and support once per day oral dosing of niraparib. Niraparib was generally well tolerated at 300 milligrams daily, with a low rate of grade 3/4 toxicities. Thrombocytopenia was identified as the dose-limiting toxicity at a daily dose level of 400 milligrams. The most frequently observed adverse events at the 300 milligram dose included grade 1/2 anemia, fatigue and nausea.   

"We are very pleased with the RECIST response rates observed in both ovarian and breast cancer patients in this trial, particularly at the 300 milligrams once daily dose that will be evaluated in our Phase 3 program," said Dr. Mary Lynne Hedley, President of TESARO. "The results of this study provide further support for the design of our planned Phase 3 trials in ovarian and breast cancer and, in particular, the potential utility of platinum sensitivity and BRCA status as predictors of response to niraparib."

Phase 1 Study Design

This Phase 1 study was designed as a two part trial to determine the maximum tolerated dose and evaluate preliminary antitumor activity, safety/tolerability, pharmacokinetic and pharmacodynamic properties of niraparib. Part A enrolled 60 patients who received a single daily dose of 30 to 400 milligrams of niraparib. Following identification of the maximum tolerated dose, Part B of the study enrolled an additional 40 patients with platinum resistant high grade serous ovarian cancer or castration-resistant prostate cancer who received a single daily dose of 300 milligrams of niraparib. Preliminary results of this study were presented at the ASCO annual meeting in 2011.

About TESARO

TESARO is an oncology-focused biopharmaceutical company dedicated to improving the lives of cancer patients by acquiring, developing and commercializing safer and more effective therapeutics. For more information, visit www.tesarobio.com.

To the extent that statements contained in this press release are not descriptions of historical facts regarding TESARO, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "anticipate," "estimate," "intend," and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. Forward-looking statements involve substantial risks and uncertainties that could cause our clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the initiation of future clinical trials, availability of data from ongoing clinical trials, expectations for regulatory approvals, and other matters that could affect the availability or commercial potential of our drug candidates. Niraparib is an investigational agent and, as such, has not been approved by any regulatory agencies.TESARO undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the business of the Company in general, see TESARO's Form 10-K for the year ended December 31, 2012.

CONTACT: Investor/Media Contact:

         Jennifer Davis

         Sr. Director, Corporate Development & Investor Relations

         +1.781.325.1116 or jdavis@tesarobio.com
distributed by
React to this article
Latest news
Date Title
08:05a TREX : Takes the Golden Hammer
08:05a POPULAR INC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
08:05a MACATAWA BANK : Other Events (form 8-K)
08:05a TEMPUR SEALY : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
08:05a QLIK TECHNOLOGIES : Cloud Offerings Unveiled: First in Business Intelligence To Deliver Data-as-a-Service
08:05a A NEW TITLE FROM NTT SOLMARE'S "SHALL WE DATE?" SERIES, "SHALL WE DATE? : Castle Break" is Now Released!
08:05a Top Military Friendly Employer, Combined Insurance, Helps Wounded Military Servicemen and Women with Donation to Luke’s Wings
08:05a KOCHAVA : First to Support Apple Watch for Brands’ Mobile App Measurement and Tracking
08:05a ENTOUCH CONTROLS : to Showcase Energy Management as a Service Solution at PRSM2015 National Conference
08:04a STEMLINE THERAPEUTICS : Change in Directors or Principal Officers (form 8-K)
Latest news
Advertisement
Hot News 
ANALYTIK JENA : Lauches New Gene Assembly Robot at SynBioBETA London 2015
BARON OIL : Says Nancy 1 Production Resumes In Colombia
SYLVANIA PLATINUM : Quarterly Report: 31 March 2015
COLLAGEN SOLUTIONS : *repeat: panmure initiates collagen solutions with 'buy' - target 18 pence
RED24 : Says Results To Beat Board Hopes, New Year Off To Good Start
Most Read News
04/26 WELLS FARGO : Which high schools were nominated for a Blumey award?
04/26 LOMBARD BANK MALTA : Approval of Ordinary Resolutions at Annual General Meeting
04/26 BLOM ASA : profits reach $91.17 million
04/26 MANCHESTER UNITED : Eden Hazard lands top PFA award
04/26 SONY : Naples Daily News, Fla., Stay Tuned column
Most recommended articles
07:59aDJSanofi SA 1Q 2015-- Forecast
07:56a Brent crude slips to $65 as dollar strengthens
07:56aDJJapan's Inpex Secures 5% Stake in Abu Dhabi Oil Concession
07:54aDJEconomists Again Cut Brazil Economic Outlook for This Year -- Survey
07:53aDJMARKET SNAPSHOT : U.S. Stocks: Futures Perk Up As Apple Results Come Into Focus
Dynamic quotes  
ON
| OFF